Clinical trials being conducted at the University of Virginia broadcast
on WWTV radio
TIRAT CARMEL, Israel, Sept. 21, 2011 /CNW/ - InSightec Ltd., the global
leader in MR guided Focused Ultrasound (MRgFUS) technology, announced
today that its investigational ExAblate(R) Neuro system has been used
in clinical studies to treat 30 patients suffering from chronic
neurological disorders. The clinical trials are being conducted by
functional neurosurgeons, neurologists and neuroradiologists in
Switzerland, and the US to evaluate the safety and initial efficacy of
the system for treating Essential Tremor, Neuropathic Pain and
Parkinson's Disease. The system is limited to investigational use only.
Neurological disorders affect millions of people worldwide and may cause
significant loss of functionality, suffering, and medication
dependency, negatively affecting the quality of life of patients and
their caretakers. For patients who do not respond to drug treatments,
procedures include deep brain stimulation, radiofrequency ablation,
radiosurgery which are either invasive or involve ionizing radiation.
These are associated with recognized risks: either high doses of
ionizing radiation or high risk of complications and side effects.
ExAblate(R) Neuro, pioneered by InSightec, is the first clinical system
to use MR guided focused ultrasound through an intact skull, combining
focused ultrasound and real time MR guidance and control, to treat
tissue deep in the brain without incisions or cutting or ionizing
"The concept of using focused ultrasound for non-invasive treatment of
brain disorders has been recognized for many years, however, vast
technical barriers had to be overcome to enable this modality to become
a reality. We have invested tremendous technological and clinical
efforts to be able to reach this point and are very encouraged by the
clinical results so far", said Eyal Zadicario, VP of R&D and Director
of the Neuro program at InSightec.
"ExAblate Neuro has demonstrated the ability to ablate targets deep in
the brain with high precision. The initial results have been
encouraging. This gives us hope that this treatment alternative could
in the future become a significant addition to the physicians'
armamentarium in treating functional brain diseases." he continued.
The intra-operative image guidance built into ExAblate Neuro is designed
to allow precision control and accurate delivery to the planned target
with continuous real time feedback throughout the treatment.
Ongoing clinical research will evaluate the ability of this technology
to reduce the risk of complications and side-effects. It may provide a
treatment option for those individuals where surgery is currently not
an option, or refuse an intervention of the brain.
Click here to view a story about the clinical trials being conducted at
the University of Virginia aired on WVTF radio on Sept 20 [http://www.wvtf.org/index.php?option=com_content&view=article&id=573:uva-pioneers-a-way-to-stop-tremors&catid=48:wvtf-news&Itemid=]
InSightec is planning to expand its Neuro research platform with
additional clinical trials for brain tumors, stroke and targeted drug
delivery to the brain.
InSightec Ltd. is a privately-held company owned by Elbit Imaging,
General Electric, MediTech Advisors, LLC and employees. It was founded
in 1999 to develop the breakthrough MR guided Focused Ultrasound
technology and transform it into the next generation operating room.
Headquartered near Haifa, Israel, the company has over 130 employees
and has invested more than $150 million in research, development, and
clinical investigations. Its U.S. headquarters are located in Dallas,
Texas. For more information, please go to: http://www.insightec.com/
ExAblate is an Image Guided, Non-invasive, Robotic Acoustic Surgery
platform. The ExAblate platform is the first to use the MR guided
focused ultrasound technology that combines MRI - to visualize the body
anatomy, plan the treatment and monitor treatment outcome in real time
- and high intensity focused ultrasound to thermally ablate tumors
inside the body non-invasively. MR thermometry, provided uniquely by
the system, allows the physician to control and adjust the treatment in
real time to ensure that the targeted tissue is treated and surrounding
non targeted tissue is spared. The ExAblate system received the
European CE mark for uterine fibroids in 2002, for pain palliation of
bone metastases in June 2007 and for adenomyosis in June 2010. It was
approved by the U.S. Food and Drug Administration in 2004 for
symptomatic uterine fibroids. Over 8,000 patients have been treated
worldwide with ExAblate systems.
SOURCE InSightec Ltd
For further information:
Waggener Edstrom Worldwide